Combination treatment to save the bladder in HER2-positive muscle-invasive bladder cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your bladder cancer is muscle-invasive (has grown into the muscle layer) but has not spread to lymph nodes or other organs.
- You have had a TURBT procedure to remove as much of the tumor as possible.
- Your tumor tests show a high amount of HER2 (called IHC 2+ or 3+).
- You are generally in good health (able to care for yourself and do daily activities).
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted medicine combined with radiation for bladder cancer that has not spread into the muscle. It is for people with a specific protein on their tumor (HER2) who cannot get or benefit from standard BCG treatment.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This study tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation therapy to treat bladder cancer while keeping the bladder intact. It aims to see if this approach can control the cancer without needing to remove the bladder.
This trial tests a combination of two medications, disitamab vedotin and toripalimab, to treat bladder cancer that has grown into the muscle layer of the bladder. The goal is to see if this treatment can save the bladder while effectively fighting the cancer.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.